These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

183 related items for PubMed ID: 12111703

  • 21. Butyrate analogue, isobutyramide, inhibits tumor growth and time to androgen-independent progression in the human prostate LNCaP tumor model.
    Gleave ME, Sato N, Sadar M, Yago V, Bruchovsky N, Sullivan L.
    J Cell Biochem; 1998 Jun 01; 69(3):271-81. PubMed ID: 9581866
    [Abstract] [Full Text] [Related]

  • 22. Androgens regulate vascular endothelial growth factor content in normal and malignant prostatic tissue.
    Joseph IB, Nelson JB, Denmeade SR, Isaacs JT.
    Clin Cancer Res; 1997 Dec 01; 3(12 Pt 1):2507-11. PubMed ID: 9815654
    [Abstract] [Full Text] [Related]

  • 23. Androgen receptor-dependent regulation of Bcl-xL expression: Implication in prostate cancer progression.
    Sun A, Tang J, Hong Y, Song J, Terranova PF, Thrasher JB, Svojanovsky S, Wang HG, Li B.
    Prostate; 2008 Mar 01; 68(4):453-61. PubMed ID: 18196538
    [Abstract] [Full Text] [Related]

  • 24. Id-1 expression induces androgen-independent prostate cancer cell growth through activation of epidermal growth factor receptor (EGF-R).
    Ling MT, Wang X, Lee DT, Tam PC, Tsao SW, Wong YC.
    Carcinogenesis; 2004 Apr 01; 25(4):517-25. PubMed ID: 14688027
    [Abstract] [Full Text] [Related]

  • 25. Inhibition of caspases by cytokine response modifier A blocks androgen ablation-mediated prostate cancer cell death in vivo.
    Srikanth S, Kraft AS.
    Cancer Res; 1998 Feb 15; 58(4):834-9. PubMed ID: 9485043
    [Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27. Enhanced androgen receptor signaling correlates with the androgen-refractory growth in a newly established MDA PCa 2b-hr human prostate cancer cell subline.
    Hara T, Nakamura K, Araki H, Kusaka M, Yamaoka M.
    Cancer Res; 2003 Sep 01; 63(17):5622-8. PubMed ID: 14500404
    [Abstract] [Full Text] [Related]

  • 28. Conversion from a paracrine to an autocrine mechanism of androgen-stimulated growth during malignant transformation of prostatic epithelial cells.
    Gao J, Arnold JT, Isaacs JT.
    Cancer Res; 2001 Jul 01; 61(13):5038-44. PubMed ID: 11431338
    [Abstract] [Full Text] [Related]

  • 29. Oncostatin M (OM) promotes the growth of DU 145 human prostate cancer cells, but not PC-3 or LNCaP, through the signaling of the OM specific receptor.
    Mori S, Murakami-Mori K, Bonavida B.
    Anticancer Res; 1999 Jul 01; 19(2A):1011-5. PubMed ID: 10368647
    [Abstract] [Full Text] [Related]

  • 30. Androgen withdrawal inhibits tumor growth and is associated with decrease in angiogenesis and VEGF expression in androgen-independent CWR22Rv1 human prostate cancer model.
    Cheng L, Zhang S, Sweeney CJ, Kao C, Gardner TA, Eble JN.
    Anticancer Res; 2004 Jul 01; 24(4):2135-40. PubMed ID: 15330153
    [Abstract] [Full Text] [Related]

  • 31. Interleukin-6 promotes androgen-independent growth in LNCaP human prostate cancer cells.
    Lee SO, Lou W, Hou M, de Miguel F, Gerber L, Gao AC.
    Clin Cancer Res; 2003 Jan 01; 9(1):370-6. PubMed ID: 12538490
    [Abstract] [Full Text] [Related]

  • 32. Monomethylated selenium inhibits growth of LNCaP human prostate cancer xenograft accompanied by a decrease in the expression of androgen receptor and prostate-specific antigen (PSA).
    Lee SO, Yeon Chun J, Nadiminty N, Trump DL, Ip C, Dong Y, Gao AC.
    Prostate; 2006 Jul 01; 66(10):1070-5. PubMed ID: 16637076
    [Abstract] [Full Text] [Related]

  • 33. Protein inhibitor of activated STAT3 regulates androgen receptor signaling in prostate carcinoma cells.
    Junicho A, Matsuda T, Yamamoto T, Kishi H, Korkmaz K, Saatcioglu F, Fuse H, Muraguchi A.
    Biochem Biophys Res Commun; 2000 Nov 11; 278(1):9-13. PubMed ID: 11071847
    [Abstract] [Full Text] [Related]

  • 34. Suppression of prostate tumor cell growth in vivo by WT1, the Wilms' tumor suppressor gene.
    Fraizer G, Leahy R, Priyadarshini S, Graham K, Delacerda J, Diaz M.
    Int J Oncol; 2004 Mar 11; 24(3):461-71. PubMed ID: 14767530
    [Abstract] [Full Text] [Related]

  • 35. Preclinical evaluation of targeted cytotoxic luteinizing hormone-releasing hormone analogue AN-152 in androgen-sensitive and insensitive prostate cancers.
    Letsch M, Schally AV, Szepeshazi K, Halmos G, Nagy A.
    Clin Cancer Res; 2003 Oct 01; 9(12):4505-13. PubMed ID: 14555524
    [Abstract] [Full Text] [Related]

  • 36. Ubiquitous mitochondrial creatine kinase is overexpressed in the conditioned medium and the extract of LNCaP lineaged androgen independent cell lines and facilitates prostate cancer progression.
    Pang B, Zhang H, Wang J, Chen WZ, Li SH, Shi QG, Liang RX, Xie BX, Wu RQ, Qian XL, Yu L, Li QM, Huang CF, Zhou JG.
    Prostate; 2009 Aug 01; 69(11):1176-87. PubMed ID: 19415690
    [Abstract] [Full Text] [Related]

  • 37. Adrenomedullin, an autocrine/paracrine factor induced by androgen withdrawal, stimulates 'neuroendocrine phenotype' in LNCaP prostate tumor cells.
    Berenguer C, Boudouresque F, Dussert C, Daniel L, Muracciole X, Grino M, Rossi D, Mabrouk K, Figarella-Branger D, Martin PM, Ouafik L.
    Oncogene; 2008 Jan 17; 27(4):506-18. PubMed ID: 17637748
    [Abstract] [Full Text] [Related]

  • 38. Androgen deprivation induces human prostate epithelial neuroendocrine differentiation of androgen-sensitive LNCaP cells.
    Yuan TC, Veeramani S, Lin FF, Kondrikou D, Zelivianski S, Igawa T, Karan D, Batra SK, Lin MF.
    Endocr Relat Cancer; 2006 Mar 17; 13(1):151-67. PubMed ID: 16601285
    [Abstract] [Full Text] [Related]

  • 39. Transdifferentiation of prostate cancer cells to a neuroendocrine cell phenotype in vitro and in vivo.
    Burchardt T, Burchardt M, Chen MW, Cao Y, de la Taille A, Shabsigh A, Hayek O, Dorai T, Buttyan R.
    J Urol; 1999 Nov 17; 162(5):1800-5. PubMed ID: 10524938
    [Abstract] [Full Text] [Related]

  • 40. Progression to androgen independence is delayed by adjuvant treatment with antisense Bcl-2 oligodeoxynucleotides after castration in the LNCaP prostate tumor model.
    Gleave M, Tolcher A, Miyake H, Nelson C, Brown B, Beraldi E, Goldie J.
    Clin Cancer Res; 1999 Oct 17; 5(10):2891-8. PubMed ID: 10537358
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 10.